Clinical trials for Cervical / Vulvar / Vaginal cancer

64 currently recruiting clinical trials
Phase 3 Colon cancer Rectal cancer Anal cancer Pancreas cancer Stomach and esophageal cancer Cervical / Vulvar / Vaginal cancer Small intestine and appendix cancer #NCT07544654 #2025-523869-22-00
Required histologic sub types
Neuroendocrine carcinoma
Required disease stage
Locally Advanced Metastatic
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive Chemotherapy
Excluded previous treatments at advanced or metastatic stage
Immunotherapy Antibody Drug Conjugates (ADC)
1 recruiting site
Boehringer Ingelheim
Phase 3 Cervical / Vulvar / Vaginal cancer #NCT07216703 #2025-521514-26-00
Required histologic types
Cervical cancer
Required histologic sub types
Squamous cell carcinoma Adenocarcinoma Adenosquamous carcinoma
Required disease stage
Metastatic
Required CPS scores
CPS Positive (>= 1)
4 recruiting sites
Merck Sharp & Dohme LLC
Phase 3 Cervical / Vulvar / Vaginal cancer #NCT05581121
Required histologic types
Cervical cancer
Required histologic sub types
Squamous cell carcinoma Adenocarcinoma Adenosquamous carcinoma
Required FIGO stages
Stage III
Required disease stage
Localized Locally Advanced
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at localized stage
Systemic Treatment-Naive
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Excluded previous treatments at localized stage
Radiotherapy
Excluded previous treatments at advanced or metastatic stage
Radiotherapy
24 recruiting sites
Institut Claudius Regaud
Phase 3 Cervical / Vulvar / Vaginal cancer #NCT03534713
Required histologic types
Cervical cancer
Required histologic sub types
Squamous cell carcinoma Adenocarcinoma Adenosquamous carcinoma
Required FIGO stages
Stage I Stage II Stage III Stage IV
Required disease stage
Localized Locally Advanced
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at localized stage
Systemic Treatment-Naive
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Excluded previous treatments at localized stage
Chemotherapy
Excluded previous treatments at advanced or metastatic stage
Chemotherapy
11 recruiting sites
Hôpital universitaire de Toulouse
Phase 2 / Phase 3 Prostate cancer Colon cancer Rectal cancer Anal cancer Pancreas cancer Stomach and esophageal cancer Cervical / Vulvar / Vaginal cancer Small intestine and appendix cancer #NCT06943755 #2025-521043-20-00
Required histologic sub types
Neuroendocrine tumor
Required disease stage
Locally Advanced Metastatic Metastatic Castration-resistant
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
6 recruiting sites
Exélixis
Phase 2 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer Head and neck cancer Sarcoma and GIST Thymus cancer Penile cancer and germ cell tumors Cervical / Vulvar / Vaginal cancer Small intestine and appendix cancer #NCT07303387 #2024-519788-16-00
Cohorte 1.D (Défience PBRM1)
Required disease stage
Metastatic Metastatic Castration-resistant
Required genetic anomalies
Other mutation
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
1 recruiting site
Gustave Roussy, Campus du cancer, Grand Paris
Phase 2 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer Head and neck cancer Sarcoma and GIST Thymus cancer Penile cancer and germ cell tumors Cervical / Vulvar / Vaginal cancer Small intestine and appendix cancer #NCT07303387 #2024-519788-16-00
Cohorte 1.F (SMARCA2 ou autres sous-unités SWI/SNF)
Required disease stage
Metastatic Metastatic Castration-resistant
Required genetic anomalies
ARID1A Other mutation
Required number of previous lines of therapy for current stage of disease
1 2
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
1 recruiting site
Gustave Roussy, Campus du cancer, Grand Paris
Phase 2 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer Head and neck cancer Sarcoma and GIST Thymus cancer Penile cancer and germ cell tumors Cervical / Vulvar / Vaginal cancer Small intestine and appendix cancer #NCT07303387 #2024-519788-16-00
Cohorte 1.E (Déficience BAP1)
Required disease stage
Metastatic Metastatic Castration-resistant
Required genetic anomalies
Other mutation
Required number of previous lines of therapy for current stage of disease
1 2
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
1 recruiting site
Gustave Roussy, Campus du cancer, Grand Paris
Phase 2 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Ovarian / Fallopian tubes / Peritoneum cancer Head and neck cancer Sarcoma and GIST Thymus cancer Penile cancer and germ cell tumors Cervical / Vulvar / Vaginal cancer Small intestine and appendix cancer #NCT07303387 #2024-519788-16-00
Cohorte 1.A (Défience en SMARCB1)
Required disease stage
Metastatic Metastatic Castration-resistant
Required genetic anomalies
SMARCB1
Required number of previous lines of therapy for current stage of disease
1
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
1 recruiting site
Gustave Roussy, Campus du cancer, Grand Paris
Phase 2 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Head and neck cancer Sarcoma and GIST Penile cancer and germ cell tumors Cervical / Vulvar / Vaginal cancer Small intestine and appendix cancer #NCT07303387 #2024-519788-16-00
Cohorte 1.Cb (Défience en ARID1A-defective, autres tumeurs)
Required disease stage
Metastatic Metastatic Castration-resistant
Required genetic anomalies
ARID1A
Required number of previous lines of therapy for current stage of disease
1 2
1 recruiting site
Gustave Roussy, Campus du cancer, Grand Paris